Page 21 - 73_01

VOL. 73 (1), 5-26, 2007 IN VITRO INVESTIGATION OF DRUG METABOLISM AND TOXICITY...

(21) LAHOZ, A.; DONATO, M. T.; CASTELL, J. V. and GÓMEZ-LECHÓN, M. J. (2006): In
(22) Vitro ADME high-throughput screening in drug preclinical development. Mini
Rev. Med. Chem. 6: 1053-1062.
(23) AITHAL, G. P.; RAMSAY, L.; DALY, A. K.; SONCHIT, N.; LEATHART, J. B.; ALEXANDER,
(24) G.; KENNA, J. G.; BACHMANN, K. A. and GHOSH, R. (2001): The use of in vitro
(25) methods to predict in vivo pharmacokinetics and drug interactions. Curr.
(26) Drug. Metab. 2: 299-314.
HUISINGA, W.; TELGMANN, R. and WULKOW, M. (2006): The virtual laboratory
(27) approach to pharmacokinetics: design principles and concepts. Drug Discov.
Today. 11: 800-805.
(28) HOUSTON, J. B. (1984): Utility of in vitro drug metabolism data in predicting
(29) in vivo metabolic clearance. Biochem. Pharmacol. 47: 1469-1479.
JONES, H. M. and HOUSTON, J. B. (2004): Substrate depletion approach for
(30) determining in vitro metabolic clearance: time dependencies in hepatocyte
(31) and microsomal incubations. Drug Metab. Dispos. 32: 973-982.
(32) NARITOMI, Y.; TERASHITA, S.; KAGAYAMA, A. and SUGIYAMA, Y. (2003): Utility of
hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic
(33) clearance in rats and humans in vivo and in vitro. Drug Metab. Dispos. 31:
(34) 580-588.
RILEY, R. J.; MCGINNITY, D. F. and AUSTIN, R. P. (2005): An unified model
for predicting human hepatic, metabolic clearance from in vitro intrinsic
clearance data in hepatocytes and microsomes. Drug Metab. Dispos. 33. 1304-
1311.
BACHMANN, K. A. and GHOSH. R. (2001): The use of in vitro methods to predict
in vivo pharmacokinetics and drug interactions. Curr. Drug Metab. 2: 299-
314.
YAMAMOTO, T.; ITOGA, H.; KOHNO, Y.; NAGATA, K. and YAMAZOE, Y. (2005):
Prediction of oral clearance from in vitro metabolic data using recombinant
CYPs: comparison among well-stirred, parallel-tube, distributed and
dispersion models. Xenobiotica. 35: 627-646.
LIU, L. and PANG, K. S. (2006): An integrated approach to model hepatic drug
clearance. Eur. J. Pharm. Sci. 29: 215-230.
GUENGERICH, F. P. (1996): In vitro techniques for studying drug metabolism.
J. Pharmacokinet. Biopharm. 24: 521-533.
GHOSAL, A.; CHOWDHYRY, S. K.; TONG, W.; HAPANGAMA, N.; YUAN, Y.; SU, A. and
ZBAIDA, S. (2006): Identification of human liver cytochrome P450 enzymes
responsible for the metabolism of lonafarnib (Sarasar). Drug Metab. Dispos.
34: 628-635.
BOOBIS, A. R.; MCKILLOP, D.; ROBINSON, D. T.; ADAMS, D. A. and MCCORMICK, D.
J. (1998): Interlaboratory comparison of the assessment of P450 activities in
human hepatic microsomal samples. Xenobiotica. 28: 493-506.
TANG, W.; WANG, R. W. and LU, A. Y. (2005): Utility of recombinant
cytochrome p450 enzymes: a drug metabolism perspective. Curr. Drug Metab.
6: 503-517.

23